Press Releases

Press Releases

May 27, 2020
Novavax acquires Praha Vaccines in Czech Republic Annual operating capacity of over 1 billion doses of COVID-19 vaccine antigen GAITHERSBURG, Md. , May 27, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious...
May 25, 2020
First participants enrolled in Phase 1 portion of clinical trial of NVX‑CoV2373 Preliminary immunogenicity and safety results expected in July 2020 Phase 2 portion to begin promptly following successful Phase 1 results GAITHERSBURG, Md. , May 25, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc....
May 11, 2020
CEPI increases investment up to $388 million for NVX‑CoV2373 vaccine development & manufacturing NVX ‑ CoV2373 Phase I trial initiating in May with preliminary results in July NanoFlu recently achieved all primary endpoints in pivotal Phase 3 clinical trial Company to host conference call today at...
Mar 11, 2020
NanoFlu top-line data from Phase 3 clinical trial expected by the end of this month Novavax awarded CEPI funding to support COVID-19 vaccine program COVID-19 Phase 1 clinical trial expected to initiate in late spring of 2020 Company to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md....
Displaying 31 - 40 of 192